8-K ·Filed May 7, 2026

AMTX

AEMETIS, INC
BEARISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001437749-26-015360
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The massive revenue miss vs consensus will likely drive a sharp sell-off. Monitor the upcoming financing updates, 45Z credit cadence, and ability to refinance near-term debt maturities. The India IPO progress and MVR project completion are potential catalysts but do not offset near-term liquidity risk.

DirectionBearish
Confidencemedium
Horizonimmediate
Final — all horizons settled through T+60d
AMTX ▼ -51.28% at T+60d
SHORT call ✓ call won +51.28% · α vs SPY +55.12% · entry $3.12 → $1.52
Entry anchored
May 6, 03:59 PM ET
via exchange tick
T+1d
-16.99%
call +16.99% · α +17.82%
$2.59
settled 5mo ago
T+5d
-29.17%
call +29.17% · α +30.67%
$2.21
settled 5mo ago
T+20d
-21.47%
call +21.47% · α +24.61%
$2.45
settled 4mo ago
T+60d
-51.28%
call +51.28% · α +55.12%
$1.52
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Aemetis reported Q1 2026 revenue of $54.6M, a 27% YoY increase but a 47% miss vs consensus of $103.1M. EPS of -$0.33 missed the -$0.20 consensus by 65%. Despite operational improvements and 45Z tax credit recognition, the massive revenue miss and continued net loss of $21.7M signal significant headwinds.

Key Financial Metrics

EPS
$-0.33
est $-0.20 · -65.0%
Revenue
$54.6M
est $103.1M · -47.0% · +27.3% YoY
Rating
strong miss
Gross Margin
5.05%

Key Facts

  • Revenue $54.6M vs consensus $103.1M (47% miss)
  • EPS -$0.33 vs consensus -$0.20 (65% miss)
  • Gross profit of $2.8M improved from gross loss of $5.1M in Q1 2025
  • Operating loss narrowed 60% YoY to $6.3M
  • Cash at end of Q1: $4.8M, down from $4.9M at Dec 2025
  • Current liabilities of $396M far exceed current assets of $34.7M
  • Accumulated deficit deepened to $661.7M

Financial Impact

Revenue shortfall of ~$48.5M vs consensus; EPS miss of $0.13

revenueepsliquidity

Risk Factors

  • Liquidity crisis with only $4.8M cash vs $293.8M current debt
  • Negative equity of $321M
  • Dependence on financing and 45Z credit monetization

Market Snapshot

Exchange
Nasdaq
Sector
Industrial Organic Chemicals
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-015360
Document: amtx20260506_8k.htm0001437749-26-015360
Document: 0001437749-26-015360-index-headers.html0001437749-26-015360
Document: 0001437749-26-015360-index.html0001437749-26-015360
Document: 0001437749-26-015360.txt0001437749-26-015360
8-K Data (Synthetic)0001437749-26-015360
4 reports for AMTX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AMTX — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
Press Release
BEARISH ★ 7/10
$1.63 $1.83▼ −12.27%▼ −11.67%$1.72 (−5.52%)
May 7, 2026
21w ago
8-K
BEARISH ★ 7/10
$3.12 $2.45▲ +21.47%▲ +24.61%$1.72 (+44.87%)
May 1, 2026
22w ago
Press Release
NEUTRAL ★ 1/10
$3.52 $2.64▼ −25.00%▼ −30.28%$1.72 (−51.14%)
Mar 12, 2026
29w ago
Press Release
MIXED ★ 6/10
$1.92 $2.27▲ +18.23%▲ +16.25%$1.72 (−10.42%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (64h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access